Sliva Daniel
Cancer Research Laboratory, Methodist Research Institute, Indianapolis, IN 46202, USA.
Integr Cancer Ther. 2003 Dec;2(4):358-64. doi: 10.1177/1534735403259066.
The popular edible mushroom Ganoderma lucidum (Reishi) has been widely used for the general promotion of health and longevity in Asian countries. The dried powder of Ganoderma lucidum was popular as a cancer chemotherapy agent in ancient China. The authors recently demonstrated that Ganoderma lucidum inhibits constitutively active transcription factors nuclear factor kappa B (NF-kappaB) and AP-1, which resulted in the inhibition of expression of urokinase-type plasminogen activator (uPA) and its receptor uPAR. Ganoderma lucidum also suppressed cell adhesion and cell migration of highly invasive breast and prostate cancer cells, suggesting its potency to reduce tumor invasiveness. Thus, Ganoderma lucidum clearly demonstrates anticancer activity in experiments with cancer cells and has possible therapeutic potential as a dietary supplement for an alternative therapy for breast and prostate cancer. However, because of the availability of Ganoderma lucidum from different sources, it is advisable to test its biologic activity.
广受欢迎的可食用蘑菇灵芝在亚洲国家已被广泛用于促进健康和延年益寿。灵芝干粉在中国古代曾作为癌症化疗药物流行。作者最近证明,灵芝可抑制组成型激活转录因子核因子κB(NF-κB)和激活蛋白-1(AP-1),从而抑制尿激酶型纤溶酶原激活剂(uPA)及其受体uPAR的表达。灵芝还抑制高侵袭性乳腺癌和前列腺癌细胞的细胞黏附和细胞迁移,表明其具有降低肿瘤侵袭性的潜力。因此,灵芝在癌细胞实验中清楚地显示出抗癌活性,作为一种膳食补充剂,对乳腺癌和前列腺癌的替代疗法可能具有治疗潜力。然而,由于灵芝来源不同,建议检测其生物活性。